With VERTIS SITA2 On Board, Merck Eyes Broad Initial Approval For Ertugliflozin
In an interview at the European Association for the Study of Diabetes meeting, Merck exec Sam Engel explains the rationale behind the clinical trial strategy for the SGLT-2 inhibitor ertugliflozin, as it gears up with partner Pfizer for filings by the end of this year.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
Merck & Co. Inc. and Pfizer Inc.'s investigational oral SGLT-2 inhibitor, ertugliflozin, has met its primary endpoints in two Phase III studies in type 2 diabetes patients – now the pair are continuing development with an 8,000 patient cardiovascular (CV) outcomes trial and plan to file the drug in US by the year end.
Heart failure worries could limit use of AstraZeneca and Takeda products, and their relabeling can only help Merck's market leader.